A rival drug failure can sometimes move a biotech stock almost as much as a company’s own clinical data.That is...
Global trade, energy transition, financial regulation, multinational corporations, and macroeconomic trends.
Categories
Recent Posts
- Microsoft’s AI expansion just hit a physical limit
- Calgro M3’s interim results reflect ongoing housing market pressures
- Strategy buys another $22 million of Bitcoin, increases planned share buybacks
- Vanguard's growth ETF turned terrible timing into $100K
- Nedbank’s R13.9bn NCBA East Africa deal complete